We came across a bearish thesis on Intellia Therapeutics, Inc. on X.com by A_May_MD. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $8 ...

Nearly three decades since the remarkable cloning of Dolly the sheep, it has all gone quiet on the human cloning front.

Cancer is a leading cause of death worldwide, and among all cancers, colorectal cancer ranks second in mortality, responsible ...

Wheat that can help make its own fertilizer is no longer a speculative idea from plant biology textbooks, it is a working prototype that could reorder how the world grows one of its staple grains. By ...

A collaborative study led by biomedical researchers Chris Lengner and M. Andrés Blanco at the School of Veterinary Medicine at the University of Pennsylvania has identified two genes that suppress ...

The convergence of genomics, systems biology, and artificial intelligence is transforming the landscape of drug discovery. Modern genomic technologies now ...

CHICAGO, Nov 8 (Reuters) - A single infusion of CRISPR Therapeutics' (CRSP.BN), opens new tab experimental gene therapy was safe and reduced levels of harmful LDL cholesterol and triglycerides by half ...

Northwestern scientists have developed a new nanostructure that supercharges CRISPR’s ability to safely and efficiently enter cells, potentially unlocking its full power to treat genetic diseases. By ...

CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap’s Substack. In this article, we will summarize the bulls’ thesis on CRSP. CRISPR Therapeutics AG (CRSP)’s share was ...

Cutting-edge gene editing technology could eradicate Down syndrome, according to Japanese scientists. Down syndrome, which causes a range of developmental differences and affects 1 in 700 newborns in ...

May 12 (Reuters) - The University of California and the University of Vienna on Monday convinced a U.S. appeals court to revive their bid for patent rights to groundbreaking CRISPR gene-editing ...